metabolic bone disease

• 代謝性骨疾患、骨代謝障害

関

bone metabolism disorder、osteopenia

WordNet

1. an impairment of health or a condition of abnormal functioning
2. remove the bones from; "bone the turkey before roasting it" (同)debone
3. the porous calcified substance from which bones are made (同)osseous_tissue
4. consisting of or made up of bone; "a bony substance"; "the bony framework of the body"
5. a shade of white the color of bleached bones (同)ivory, pearl, off-white
6. rigid connective tissue that makes up the skeleton of vertebrates (同)os
7. having bones as specified; "his lanky long-boned body"
8. having had the bones removed; "a boneless rib roast"; "a boned (or deboned) fish" (同)deboned
9. of or relating to metabolism; "metabolic rate"
10. undergoing metamorphosis (同)metabolous
11. caused by or altered by or manifesting disease or pathology; "diseased tonsils"; "a morbid growth"; "pathologic tissue"; "pathological bodily processes" (同)morbid, pathologic, pathological

PrepTutorEJDIC

1. (体の)『病気』,疾患 / (精神・道徳などの)病気,病弊
2. 女性の話術芸人 =diseur
3. 〈C〉骨 / 〈U〉骨を作っている物質,骨質 / 《複数形で》骨格;死骸(がい) / 〈魚など〉‘の'骨を取る
4. (魚など)骨を取り除いた / (衣服が)(コルセットなどで)骨で張りをつけた[ような]
5. 新陳代謝の
6. 病気にかかった / 病的な,不健全な(morbid)

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/08/07 10:01:46」(JST)

wiki en

[Wiki en表示]

Metabolic bone disease
Classification and external resources
MeSH	D001851

Metabolic bone disease is an umbrella term referring to abnormalities of bones caused by a broad spectrum of disorders.

Most commonly these disorders are caused by abnormalities of minerals such as calcium, phosphorus, magnesium or vitamin D leading to dramatic clinical disorders that are commonly reversible once the underlying defect has been treated. These disorders are to be differentiated from a larger group of genetic bone disorders where there is a defect in a specific signaling system or cell type that causes the bone disorder. There may be overlap. For example, genetic or hereditary hypophosphatemia may cause the metabolic bone disorder osteomalacia. Although there is currently no treatment for the genetic condition, replacement of phosphate often corrects or improves the metabolic bone disorder.

Conditions considered to be metabolic bone disorders

• osteoporosis
• osteomalacia (adults) & rickets (children)
• osteitis fibrosa cystica
• Paget's disease of bone
• pyramiding (turtles)

Osteoporosis is due to causal factors like atrophy of disuse and gonadal deficiency. Hence osteoporosis is common in post menopausal women and in men above 50 yrs. Hypercorticism may also be causal factor- osteoporosis may be seen as a feature of Cushing's syndrome.

External links

• Identification and treatment of metabolic bone disease
• Metabolic Bone Disease
• Squirrel Wildlife Rehabilitators-Metabolic Bone Disease
• Metabolic Bone Disease in reptiles - An in depth review.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 慢性腎臓病に伴う骨・ミネラル代謝異常（CKD-MBD）の概要 overview of chronic kidney disease mineral bone disease ckd mbd
• 2. 原発性胆汁性肝硬変における代謝性骨疾患 metabolic bone disease in primary biliary cirrhosis
• 3. 骨軟化症の臨床症状、診断、および治療 clinical manifestations diagnosis and treatment of osteomalacia
• 4. 小児におけるくる病の概要 overview of rickets in children
• 5. 閉経前の骨粗鬆症の疫学および病因 epidemiology and etiology of premenopausal osteoporosis

English Journal

• Omic-profiling in breast cancer metastasis to bone: implications for mechanisms, biomarkers and treatment.

• Wood SL, Westbrook JA, Brown JE.Author information Wolfson Molecular Imaging Centre, University of Manchester, Manchester M20 3LJ, UK. Electronic address: steven.wood@manchester.ac.uk.AbstractDespite well-recognised advances in breast cancer treatment, there remain substantial numbers of patients who develop metastatic disease, of which up to 70% involves spread to bone, resulting in skeletal complications which have a major negative impact on mortality and quality of life. Bisphosphonates and newer bone-targeted agents have reduced the prevalence of skeletal complications, yet there remains significant unmet clinical need, particularly for the development of more specific therapies for the prevention and treatment of metastatic bone disease, for the prediction of risk of its development in individual patients and for the prediction of response to treatments. Modern 'omic' strategies can potentially make a major contribution to meeting this need. Technological advances in the field of nucleic acid sequencing, mass spectrometry and metabolic profiling have driven progress in genomics, transcriptomics (functional genomics), proteomics and metabolomics. This review appraises the recent application of these approaches to studies of breast cancer metastasis (particularly to bone), with a focus on understanding how omic approaches may lead to new therapeutic options and to novel biomarker molecules or molecular signatures with potential value in clinical practise. The increasingly recognised need for rigorous sample quality control and both pre-clinical and clinical validation to meet the ultimate goals of clinical utility and patient benefit is discussed. Future directions of omic driven research in breast cancer metastasis are considered, in particular micro-RNAs and their role in the post-transcriptional regulation of gene function and the possible role of cancer-stem cells and epigenetic modifications in the development of distant metastases.
• Cancer treatment reviews.Cancer Treat Rev.2014 Feb;40(1):139-52. doi: 10.1016/j.ctrv.2013.07.006. Epub 2013 Aug 16.
• Despite well-recognised advances in breast cancer treatment, there remain substantial numbers of patients who develop metastatic disease, of which up to 70% involves spread to bone, resulting in skeletal complications which have a major negative impact on mortality and quality of life. Bisphosphonat
• PMID 23958309

• Two novel mutations in the SLCO2A1 gene in a Chinese patient with primary hypertrophic osteoarthropathy.

• Zhang Z1, He JW2, Fu WZ2, Zhang CQ3, Zhang ZL4.Author information 1Metabolic Bone Disease and Genetic Research Unit, Department of Osteoporosis and Bone Diseases, Shanghai Jiao Tong University Affiliated the Sixth People's Hospital, Shanghai 200233, 600 Yi-Shan Rd., PR China; Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated the Sixth People's Hospital, Shanghai 200233, 600 Yi-Shan Rd., PR China.2Metabolic Bone Disease and Genetic Research Unit, Department of Osteoporosis and Bone Diseases, Shanghai Jiao Tong University Affiliated the Sixth People's Hospital, Shanghai 200233, 600 Yi-Shan Rd., PR China.3Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated the Sixth People's Hospital, Shanghai 200233, 600 Yi-Shan Rd., PR China.4Metabolic Bone Disease and Genetic Research Unit, Department of Osteoporosis and Bone Diseases, Shanghai Jiao Tong University Affiliated the Sixth People's Hospital, Shanghai 200233, 600 Yi-Shan Rd., PR China. Electronic address: zzl2002@medmail.com.cn.AbstractPrimary hypertrophic osteoarthropathy (PHO) is a rare monogenetic disease characterized by digital clubbing, periostosis and pachydermia. Mutations in the 15-hydroxy-prostaglandin dehydrogenase (HPGD) gene and solute carrier organic anion transporter family member 2A1 (SLCO2A1) gene have been shown to be associated with PHO. Here, we described clinical characteristics in a Chinese patient with PHO, and identified two novel mutations in SLCO2A1: a heterozygous guanine-to-thymidine transition at the invariant -1 position of the acceptor site of intron 2 (c.235-1G>T) and a heterozygous missense mutation p.Pro219Leu (c.656C>T) in exon 5.
• Gene.Gene.2014 Jan 25;534(2):421-3. doi: 10.1016/j.gene.2013.10.051. Epub 2013 Nov 1.
• Primary hypertrophic osteoarthropathy (PHO) is a rare monogenetic disease characterized by digital clubbing, periostosis and pachydermia. Mutations in the 15-hydroxy-prostaglandin dehydrogenase (HPGD) gene and solute carrier organic anion transporter family member 2A1 (SLCO2A1) gene have been shown
• PMID 24185079

• Effects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk-hydroxyapatite films.

• Hayden RS, Vollrath M, Kaplan DL.Author information Department of Biomedical Engineering, Tufts University, 4 Colby St., Medford, MA 02155, USA.AbstractThe goal of this study was to explore the effects of osteoporosis-related therapeutics on bone remodeling in vitro. A previously established bone-tissue mimetic system consisting of silk protein biomaterials in combination with hydroxyapatite and human cells was used for the study. Silk-hydroxyapatite films were pre-complexed with the non-nitrogenous bisphosphonate clodronate or the nitrogenous bisphosphonate alendronate and cultured with THP-1 human acute monocytic leukemia cell line-derived osteoclasts, human mesenchymal stem cell derived osteoblasts or a direct co-culture of the two cell types. Metabolic activity, calcium deposition and alkaline phosphatase activity were assessed over 12weeks, and reconstructed remodeled biomaterial surfaces were also evaluated for quantitative morphological changes. Increased metabolic activity and increased roughness were found on the clodronate-complexed biomaterial substrates remodeled by osteoblasts and co-cultures of osteoblasts with osteoclasts, even at doses high enough to cause a 90% decrease in osteoclast metabolic activity. Films complexed with low doses of alendronate resulted in increased metabolic activity and calcium deposition by osteoblasts, while higher doses were similarly toxic among osteoclasts, osteoblasts and co-cultures. These results point to the utility of these well-defined bone-mimetic in vitro cultures as useful screens for therapeutics for bone-related diseases, particularly with the ability to conduct studies for extended duration (here for 12weeks) and with pre-complexed drugs to mimic conditions found in vivo.
• Acta biomaterialia.Acta Biomater.2014 Jan;10(1):486-93. doi: 10.1016/j.actbio.2013.09.028. Epub 2013 Oct 1.
• The goal of this study was to explore the effects of osteoporosis-related therapeutics on bone remodeling in vitro. A previously established bone-tissue mimetic system consisting of silk protein biomaterials in combination with hydroxyapatite and human cells was used for the study. Silk-hydroxyapati
• PMID 24096150

Japanese Journal

• 全身性疾患としての慢性腎臓病

• 日本医科大学医学会雑誌 12(1), 7-14, 2016
• NAID 130005132880

• 骨粗鬆症の危険因子としての慢性の精神的ストレス

• 産業医科大学雑誌 37(4), 245-253, 2015-12-01
• NAID 110010015402

• 専門医試験をめざす症例問題トレーニング 代謝性骨疾患(骨粗鬆症を含む)

• 整形外科 = Orthopedic surgery 66(11), 1215-1218, 2015-10
• NAID 40020598535

Related Links

• Metabolic bone disease | definition of metabolic bone disease ...

metabolic bone disease Any defect in bone absorption or deposition that alters the PTH/calcium-phosphate/vitamin D axis, often with increased bone fragility. Aetiology • Acquired—Fibrous dysplasia, Langerhans cell histiocytosis ...

• Metabolic Bone Disease - definition of Metabolic Bone ...

For patients with stage 5 CKD who have low bone mineral density or fragility fractures, a double tetracycline-labeled bone biopsy is necessary to rule out other causes of metabolic bone disease and confirm a diagnosis of osteoporosis.

---

★リンクテーブル★

リンク元	「骨代謝障害」「代謝性骨疾患」「bone metabolism disorder」
拡張検索	「metabolic bone disease in premature infant」
関連記事	「disease」「metabolic」「bone」

「骨代謝障害」

　　[★]

英

metabolic bone disease、bone metabolism disorder

関

代謝性骨疾患

「代謝性骨疾患」

　　[★]

英

metabolic bone disease

関

オステオペニア、骨代謝障害

「bone metabolism disorder」

　　[★]

骨代謝障害

関

metabolic bone disease

「metabolic bone disease in premature infant」

　　[★] 未熟児代謝性骨疾患

「disease」

　　[★]

• n.

疾患：illnessより厳密な概念。「ある臓器に明確な障害が確認され、それによって症状が出ているとはっきり説明できる場合」 (PSY.9)

特定の原因、病態生理、症状、経過、予後、病理組織所見が全てそろった場合 (PSY.9)

• something that is very wrong with people's attitudes, way of life or with society.

関

ail、ailment、disease entity、disorder、ill、illness、malady、sick、sickness

• 注意

disease ≠ illness ≠ disorder

　 　 　

「metabolic」

　　[★]

• adj.

• 代謝性の、代謝的な、メタボリックな

関

metabolically

　 　 　

「bone」

　　[★] 骨